NCT04603287View on ClinicalTrials.gov

A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 17, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Locally Advanced or Metastatic Epithelial Tumor

Interventions

DRUG

SI-B001

Administration by intravenous infusion.

Trial Locations (3)

510006

Sun Yat-sen University Cancer Center, Guangzhou

Unknown

West China Hospital，Sichuan University, Chengdu

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

collaborator

SystImmune Inc.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT04603287 - A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors | Biotech Hunter | Biotech Hunter